| 0.7489 0.029 (4.01%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.01 | 1-year : | 1.13 |
| Resists | First : | 0.86 | Second : | 0.96 |
| Pivot price | 0.79  |
|||
| Supports | First : | 0.7 | Second : | 0.58 |
| MAs | MA(5) : | 0.76  |
MA(20) : | 0.78 |
| MA(100) : | 1.01 |
MA(250) : | 1.21 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7.8 |
D(3) : | 17.4 |
| RSI | RSI(14): 44.2 |
|||
| 52-week | High : | 5.07 | Low : | 0.67 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ABVC ] has closed above bottom band by 27.8%. Bollinger Bands are 31.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.75 - 0.75 | 0.75 - 0.76 |
| Low: | 0.7 - 0.7 | 0.7 - 0.71 |
| Close: | 0.74 - 0.75 | 0.75 - 0.76 |
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Thu, 25 Jul 2024
ABVC BioPharma (NASDAQ:ABVC) Stock Price Down 7.6% - Defense World
Tue, 23 Jul 2024
ABVC BioPharma Corrects Licensing Deal Financials - TipRanks
Wed, 17 Jul 2024
ABVC BioPharma's CEO Discusses New Drug Development and AI Integration - Proactive Investors USA
Fri, 12 Jul 2024
ABVC BioPharma faces Nasdaq delisting over share price - Investing.com
Wed, 22 May 2024
ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24M - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 8.26e+006 (%) |
| Held by Institutions | 23.6 (%) |
| Shares Short | 435 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.73e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -285 % |
| Return on Assets (ttm) | 841.5 % |
| Return on Equity (ttm) | -48.5 % |
| Qtrly Rev. Growth | 25360 % |
| Gross Profit (p.s.) | -116.59 |
| Sales Per Share | -331.56 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.87 |
| Dividend | 0 |
| Forward Dividend | 227870 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|